Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
OTCPK:TEVJF's Cash to Debt is ranked lower than
81% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. OTCPK:TEVJF: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:TEVJF' s 10-Year Cash to Debt Range
Min: 0.07   Max: N/A
Current: 0.31

Equity to Asset 0.48
OTCPK:TEVJF's Equity to Asset is ranked lower than
71% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OTCPK:TEVJF: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:TEVJF' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.6
Current: 0.48

0.39
0.6
Interest Coverage 13.17
OTCPK:TEVJF's Interest Coverage is ranked lower than
76% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2145.51 vs. OTCPK:TEVJF: 13.17 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TEVJF' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 13.17

3.6
328.25
F-Score: 8
Z-Score: 2.02
M-Score: -2.82
WACC vs ROIC
5.20%
9.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.41
OTCPK:TEVJF's Operating margin (%) is ranked higher than
80% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. OTCPK:TEVJF: 18.41 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:TEVJF' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 18.41

8.12
26.78
Net-margin (%) 13.61
OTCPK:TEVJF's Net-margin (%) is ranked higher than
77% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. OTCPK:TEVJF: 13.61 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:TEVJF' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 13.61

5.73
21.09
ROE (%) 11.87
OTCPK:TEVJF's ROE (%) is ranked higher than
66% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. OTCPK:TEVJF: 11.87 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:TEVJF' s 10-Year ROE (%) Range
Min: 4.23   Max: 27
Current: 11.87

4.23
27
ROA (%) 5.90
OTCPK:TEVJF's ROA (%) is ranked higher than
62% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. OTCPK:TEVJF: 5.90 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:TEVJF' s 10-Year ROA (%) Range
Min: 2.26   Max: 13.11
Current: 5.9

2.26
13.11
ROC (Joel Greenblatt) (%) 42.34
OTCPK:TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.39 vs. OTCPK:TEVJF: 42.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:TEVJF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.89   Max: 49.79
Current: 42.34

12.89
49.79
Revenue Growth (3Y)(%) 4.80
OTCPK:TEVJF's Revenue Growth (3Y)(%) is ranked lower than
52% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. OTCPK:TEVJF: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:TEVJF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.8   Max: 23.4
Current: 4.8

4.8
23.4
EBITDA Growth (3Y)(%) 10.00
OTCPK:TEVJF's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. OTCPK:TEVJF: 10.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:TEVJF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.5   Max: 47.2
Current: 10

-10.5
47.2
EPS Growth (3Y)(%) 4.80
OTCPK:TEVJF's EPS Growth (3Y)(%) is ranked higher than
53% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OTCPK:TEVJF: 4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:TEVJF' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.6   Max: 69.8
Current: 4.8

-25.6
69.8
» OTCPK:TEVJF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.00
TEVJF's P/E(ttm) is ranked higher than
74% of the 530 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.90 vs. TEVJF: 19.00 )
Ranked among companies with meaningful P/E(ttm) only.
TEVJF' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1072.29
Current: 19

10.53
1072.29
Forward P/E 12.05
TEVJF's Forward P/E is ranked higher than
88% of the 426 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. TEVJF: 12.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.00
TEVJF's PE(NRI) is ranked higher than
74% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.70 vs. TEVJF: 19.00 )
Ranked among companies with meaningful PE(NRI) only.
TEVJF' s 10-Year PE(NRI) Range
Min: 10.53   Max: 938.25
Current: 19

10.53
938.25
P/B 2.30
TEVJF's P/B is ranked higher than
67% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. TEVJF: 2.30 )
Ranked among companies with meaningful P/B only.
TEVJF' s 10-Year P/B Range
Min: 1.37   Max: 4.88
Current: 2.3

1.37
4.88
P/S 2.60
TEVJF's P/S is ranked higher than
57% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. TEVJF: 2.60 )
Ranked among companies with meaningful P/S only.
TEVJF' s 10-Year P/S Range
Min: 1.58   Max: 5.86
Current: 2.6

1.58
5.86
PFCF 15.90
TEVJF's PFCF is ranked higher than
80% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.02 vs. TEVJF: 15.90 )
Ranked among companies with meaningful PFCF only.
TEVJF' s 10-Year PFCF Range
Min: 8.45   Max: 39.85
Current: 15.9

8.45
39.85
POCF 9.41
TEVJF's POCF is ranked higher than
84% of the 444 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.56 vs. TEVJF: 9.41 )
Ranked among companies with meaningful POCF only.
TEVJF' s 10-Year POCF Range
Min: 6.56   Max: 26.77
Current: 9.41

6.56
26.77
EV-to-EBIT 15.94
TEVJF's EV-to-EBIT is ranked higher than
70% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.90 vs. TEVJF: 15.94 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 991
Current: 15.94

11.7
991
PEG 3.96
TEVJF's PEG is ranked lower than
59% of the 246 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. TEVJF: 3.96 )
Ranked among companies with meaningful PEG only.
TEVJF' s 10-Year PEG Range
Min: 0.38   Max: 271
Current: 3.96

0.38
271
Shiller P/E 21.50
TEVJF's Shiller P/E is ranked higher than
75% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.08 vs. TEVJF: 21.50 )
Ranked among companies with meaningful Shiller P/E only.
TEVJF' s 10-Year Shiller P/E Range
Min: 14.03   Max: 75
Current: 21.5

14.03
75
Current Ratio 1.26
TEVJF's Current Ratio is ranked lower than
81% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. TEVJF: 1.26 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s 10-Year Current Ratio Range
Min: 1.06   Max: 2.95
Current: 1.26

1.06
2.95
Quick Ratio 0.93
TEVJF's Quick Ratio is ranked lower than
79% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. TEVJF: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 2.19
Current: 0.93

0.68
2.19
Days Inventory 185.78
TEVJF's Days Inventory is ranked lower than
78% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.86 vs. TEVJF: 185.78 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s 10-Year Days Inventory Range
Min: 131.65   Max: 208.14
Current: 185.78

131.65
208.14
Days Sales Outstanding 99.27
TEVJF's Days Sales Outstanding is ranked lower than
69% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. TEVJF: 99.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s 10-Year Days Sales Outstanding Range
Min: 95.91   Max: 153.21
Current: 99.27

95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.10
TEVJF's Dividend Yield is ranked higher than
73% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. TEVJF: 2.10 )
Ranked among companies with meaningful Dividend Yield only.
TEVJF' s 10-Year Dividend Yield Range
Min: 0.2   Max: 3.26
Current: 2.1

0.2
3.26
Dividend Payout 0.42
TEVJF's Dividend Payout is ranked higher than
73% of the 404 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. TEVJF: 0.42 )
Ranked among companies with meaningful Dividend Payout only.
TEVJF' s 10-Year Dividend Payout Range
Min: 0.04   Max: 5
Current: 0.42

0.04
5
Dividend growth (3y) 15.30
TEVJF's Dividend growth (3y) is ranked higher than
72% of the 240 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. TEVJF: 15.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
TEVJF' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 15.3

-6.7
80.9
Yield on cost (5-Year) 5.96
TEVJF's Yield on cost (5-Year) is ranked higher than
94% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. TEVJF: 5.96 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVJF' s 10-Year Yield on cost (5-Year) Range
Min: 0.57   Max: 9.25
Current: 5.96

0.57
9.25
Share Buyback Rate 1.30
TEVJF's Share Buyback Rate is ranked higher than
88% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.60 vs. TEVJF: 1.30 )
Ranked among companies with meaningful Share Buyback Rate only.
TEVJF' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
TEVJF's Price/DCF (Projected) is ranked higher than
89% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TEVJF: 1.00 )
Ranked among companies with meaningful Price/DCF (Projected) only.
TEVJF' s 10-Year Price/DCF (Projected) Range
Min: 0.61   Max: 29.17
Current: 1

0.61
29.17
Price/Median PS Value 0.80
TEVJF's Price/Median PS Value is ranked higher than
89% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. TEVJF: 0.80 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVJF' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 1.79
Current: 0.8

0.49
1.79
Earnings Yield (Greenblatt) 6.30
TEVJF's Earnings Yield (Greenblatt) is ranked higher than
81% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. TEVJF: 6.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
TEVJF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 6.3

0.1
8.6
Forward Rate of Return (Yacktman) 0.35
TEVJF's Forward Rate of Return (Yacktman) is ranked lower than
64% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.59 vs. TEVJF: 0.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
TEVJF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.4   Max: 51.2
Current: 0.35

-0.4
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TEVA.USA, TEV.Germany, TEVA.Switzerland, TEVA.Israel,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Stanley Druckenmiller's Top 5 New Stocks May 25 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Analysts Weigh in on Auspex Pharmaceuticals Following Teva Acquisition Mar 31 2015 
Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 

More From Other Websites
Teva buying up shares of Mylan May 29 2015
Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog May 29 2015
FTC's Drug Settlement a Win for the Lawyers May 29 2015
Teva, FTC Reach $1.2 Billion Settlement on Cephalon’s Provigil May 28 2015
Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
In Wake of Teva Deal, FTC Hopes to 'Send a Strong Signal' To Pharma May 28 2015
Teva to pay $1.2 bn fine to settle US antitrust case May 28 2015
With A $1.2 Billion Hammer, The FTC Closes Loophole To Prevent Generic Drugs May 28 2015
Teva to pay $1.2 billion in drug-delay settlement May 28 2015
Teva to pay $1.2 billion in drug-delay settlement May 28 2015
Teva pays $1.2bn in US antitrust drugs case May 28 2015
Teva reaches $1.2B settlement with the FTC May 28 2015
Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
Teva pays $1.2 billion to settle pay-for-delay allegations May 28 2015
U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil May 28 2015
Teva agrees to $1.2B FTC anti-trust settlement May 28 2015
Short Sellers More Selective on Big Pharma Stocks May 28 2015
Teva Agrees to $1.2B Provigil Settlement With FTC May 28 2015
Teva to Pay $1.2 Billion to Resolve FTC Pay for Delay Lawsuit May 28 2015
U.S. settles 'pay for delay' fight with drugmaker Cephalon May 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK